CD4 and neoplasm: In the group receiving 12.5 mg/kg of MP4, Treg populations (CD4+FoxP3+) were reduced by 50% in tumor samples (Figure 6C), but not in blood and spleen, indicating a more specific targeting of Tregs in the TME contributing to the anti-tumor immune response.